ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK 1513525 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 2.1M shares as of May 6, 2026 (10-Q). Share count fell from 28.5M to 1.2M between May 12, 2023 and Aug 18, 2023, a pattern consistent with a reverse split (roughly 1-for-23); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series F Warrants | 552,940 | $7.75 | — | — |
| Pre Funded Warrants | 230,352 | not tagged | — | — |
| Series E Warrants | 207,627 | $7.75 | — | — |
| Series B1 Warrants | 99,290 | not tagged | — | — |
| Series C Warrants | 92,000 | $3.125 | — | — |
| Series B Warrants | 56,737 | not tagged | — | — |
| Warrant | 46,000 | $8.75 | — | — |
| Series C1 Warrants | 8,924 | $18.5 | — | — |
| Series D Warrants | 4,244 | $10.9375 | — | — |
| New Warrants | not tagged | $23.125 | — | — |
| Stock Warrants | not tagged | not tagged | — | FV $500,000 |
| Prior Warrants | not tagged | $8.75 | — | — |
Tranches exactly as the company dimensioned them in its 10-K filed Mar 5, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 2.3M underlying shares, as reported Dec 31, 2023 (10-K).
Reported exercise price: $2.82 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $300,000 as of Dec 31, 2025.
Rough fully diluted estimate: 4.4M = 2.1M O/S + 2.3M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed May 8, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 2.1M | May 6, 2026 |
| + Series F Warrants (if exercised) | 552,940 | Nov 25, 2025 |
| + Pre Funded Warrants (if exercised) | 230,352 | Jun 18, 2025 |
| + Series E Warrants (if exercised) | 207,627 | Nov 25, 2025 |
| + Series B1 Warrants (if exercised) | 99,290 | Jun 17, 2025 |
| + Series C Warrants (if exercised) | 92,000 | Dec 31, 2025 |
| + Series B Warrants (if exercised) | 56,737 | May 2, 2025 |
| + Warrant (if exercised) | 46,000 | Mar 1, 2024 |
| + Series C1 Warrants (if exercised) | 8,924 | Dec 31, 2025 |
| + Series D Warrants (if exercised) | 4,244 | Dec 31, 2025 |
| Fully diluted estimate | 3.4M | +60.6% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $4.2Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 3 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ADIL workspace